Overview

Bevacizumab Therapy for Brain Arteriovenous Malformation

Status:
Completed
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
Bevacizumab Therapy for brain arteriovenous malformation that is not amenable to surgical intervention.
Phase:
Phase 1
Details
Lead Sponsor:
University of California, San Francisco
Treatments:
Bevacizumab